Denali Therapeutics

On June 2nd, Denali team members joined the San Francisco Giants and Major League Baseball (MLB) to celebrate the fourth annual Lou Gehrig Day, honoring the legendary player and raising awareness for Amyotrophic Lateral Sclerosis (ALS).  It's inspiring to see the MLB community unite to honor Lou Gehrig and support those affected by ALS. The camaraderie among fans, players, and organizations demonstrates the power of collective efforts in raising awareness and advancing ALS research.  #LouGehrigDay #EndALS #DenaliTherapeutics #SanFranciscoGiants #MLB

We are pleased to share the FDA has selected DNL126 (ETV:SGSH), an investigational treatment for MPS IIIA (Sanfilippo syndrome Type A), for participation in the Support for clinical Trials Advancing Rare disease Therapeutics (START) Pilot Program. The FDA's CDER and CBER divisions jointly launched START in September 2023 to further accelerate development of rare disease therapeutics. Participating in START is a significant opportunity to collaborate further with the FDA to solve challenges unique to rare disease drug development and determine the most efficient development path for DNL126 in MPS IIIA, a devastating and progressive disease for which there are no approved treatments. Read our press release here: https://lnkd.in/gFyRdfsN

Our team was deeply inspired by "Love & Life: No Ordinary Campaign", a documentary highlighting the transformative power of love, hope, and activism within the ALS community. It was an extraordinary experience to watch this film alongside many members of the community during ALS Awareness month. Thank you Sandra Abrevaya, Brian Wallach, and Synapticure Inc. for inviting us to join this screening. The documentary will be available on Prime Video May 28th. #ALSawareness #ForLoveAndLife #NoOrdinaryCampaign

May 15 is International MPS Awareness Day and the global MPS community is declaring "It's About Time" for increased awareness, accelerated research, and improved access to care worldwide. Discover how our team is supporting this message and raising their voices for change.  #MPSAwareness 

We're thrilled to share that our Chief People Officer, Cindy Dunkle, has been named as one of the Top 25 Executives in Biotechnology for 2024 by The Healthcare Technology Report. We are inspired everyday by Cindy's passion and dedication to foster an inclusive and inventive culture where each individual at Denali can thrive and, together, #DefeatDegeneration. Join us in congratulating Cindy! Read more here: https://lnkd.in/gke-Jubk #Leadership

We reported our first quarter 2024 financial results and business highlights. Read our press release: https://lnkd.in/gkB5E_pr

Our CEO and co-founder Ryan Watts, will moderate fireside chats with Former CEO, Chairman of Illumina, and Denali Board member, Jay Flatley, and ALS advocates Sandra Abrevaya and Brian Wallach following their presentations at BioHive Utah Live: Utah’s Life Sciences and Healthcare Innovation Event on May 8. Our Chief People Officer and BioHive Board Vice-Chair Cindy Dunkle will help kick-off the event and close with a call to action to advance Utah’s growing life sciences community. For the full agenda, visit the link here: https://biohivelive.com/

Thank you, Matthew Ellinwood, Chief Scientific Officer at the National MPS Society, and Mark Dant, Executive Director of The Ryan Foundation for Rare Disease Research, for your powerful words advocating for change in how we evaluate treatments in rare diseases. Read their compelling article to understand why change is imperative now: https://lnkd.in/gCwwwmqy 

We are pleased to share that the HEALEY ALS Platform Trial has completed enrollment for Regimen G, which is evaluating our eIF2B agonist DNL343 as a potential treatment for people living with ALS. The HEALEY ALS Platform Trial, led by the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital in collaboration with the Northeast ALS Consortium (NEALS), aims to accelerate the path to new ALS therapies by testing multiple experimental treatments at once. We are excited to be a part of this innovative effort and look forward to continued collaboration with the ALS community to advance the science with the goal of bringing forth effective treatments. Read more here: https://lnkd.in/gPFE5ejJ

In recognition of Parkinson's Awareness Month, we were honored to partner with The Michael J. Fox Foundation for Parkinson's Research in welcoming three extraordinary advocates, Ethan Henderson, Catherine Armsden, to our offices, and Fiona Davis, who joined us virtually. Their tireless commitment and passion for advocacy not only inspires our daily work but also highlights the importance of collaboration as we strive to address Parkinson's disease. Thank you for joining us to raise awareness through sharing your individual perspectives. Visit Michael J. Fox Foundation Parkinson’s Awareness Month Hub to learn more ways to drive awareness of PD. https://lnkd.in/dcGWRX7